Literature DB >> 16830250

[Amyotrophic lateral sclerosis--when planning is almost too late].

Veronika Praxmarer1, Heinz Lahrmann.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a disease with progressive muscle weakness, also affecting respiratory muscles. In the terminal phase most patients experience a progression. Nutrition, speech and breathing capacity decrease. It is important to inform the patient and relatives in time and to give them a chance to decide. "Care Planning" and "Advance Directives" especially concerning ventilation reduces fear and helps the doctors and carers to decide, following the will of the patient. Nobody knows the speed of the progression. The patient in this case had few subjective symptoms at the time of the family conference. Progression till death lasted one month only. Treatment of his dyspnoe was not optimised, but during care all decisions were based on the actual will of the patient. Generally nocturnal hypoventilation, for instance non-invasive ventilation by BiPAP-mode, can relieve symptoms of dyspnoe in ALS patients. Low-dose morphine and/or benzodiazepine relieve respiratory discomfort and remove the negative spiral of dysnoe-fear-dyspnoe. Oxygen therapy is usually not needed (only in the very last stages of the disease) and is not recommended especially during the night. Hypercapnia can occur because of hypoventilation. This can cause growing unconsciousness and maybe death during sleep. Prolonging life is only possible by invasive long-term ventilation with all the problems of intensive care measures. The patient could have been given low dose morphine from the time of the family conference. Ventilation by CPAP-mode was insufficient for him.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830250     DOI: 10.1007/s10354-006-0293-6

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  5 in total

1.  [Provisions for long-term at home ventilated patient: consensus recommendations of the Austrian Society for Lung Diseases and Tuberculosis].

Authors:  Sylvia E Hartl; Werner Heindl; Heinz Lahrmann; Eveline Kink; Beatrice Oberwaldner; Andreas Pfleger; Wolfgang Schreiber; Michael Studnicka; Monika Wild; Maximilian S Zach
Journal:  Wien Klin Wochenschr       Date:  2004       Impact factor: 1.704

2.  Bipap improves survival and rate of pulmonary function decline in patients with ALS.

Authors:  K A Kleopa; M Sherman; B Neal; G J Romano; T Heiman-Patterson
Journal:  J Neurol Sci       Date:  1999-03-15       Impact factor: 3.181

Review 3.  Palliative care in amyotrophic lateral sclerosis.

Authors:  G D Borasio; R Voltz; R G Miller
Journal:  Neurol Clin       Date:  2001-11       Impact factor: 3.806

4.  Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes.

Authors:  A H Moss; E A Oppenheimer; P Casey; P A Cazzolli; R P Roos; C B Stocking; M Siegler
Journal:  Chest       Date:  1996-07       Impact factor: 9.410

5.  [Nocturnal noninvasive ventilation of children and adolescents with neuromuscular diseases: effect on sleep and symptoms].

Authors:  Uwe Mellies; Christian Dohna-Schwake; Regine Ragette; Helmut Teschler; Thomas Voit
Journal:  Wien Klin Wochenschr       Date:  2003-12-30       Impact factor: 2.275

  5 in total
  1 in total

1.  [BIPAP-mask-ventilation in terminal amyotrophic lateral sclerosis (ALS)].

Authors:  Theresa Sellner-Pogány; Heinz Lahrmann
Journal:  Wien Med Wochenschr       Date:  2009-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.